A multi-center, prospective, randomized, double-blind, placebo-controlled, two-arm, phase IV study to investigate the influence of a continuous combined estrogen-progestin regimen containing 2 mg estradiol valerate and 2 mg dienogest (Climodien/Lafamme) on the fat distribution in otherwise healthy early postmenopausal women

Trial Profile

A multi-center, prospective, randomized, double-blind, placebo-controlled, two-arm, phase IV study to investigate the influence of a continuous combined estrogen-progestin regimen containing 2 mg estradiol valerate and 2 mg dienogest (Climodien/Lafamme) on the fat distribution in otherwise healthy early postmenopausal women

Completed
Phase of Trial: Phase IV

Latest Information Update: 05 May 2009

At a glance

  • Drugs Estradiol valerate/dienogest (Primary)
  • Indications Menopausal syndrome
  • Focus Pharmacodynamics
  • Sponsors Bayer
  • Most Recent Events

    • 05 May 2009 Actual end date (1 Aug 2004) added as reported by ClinicalTrials.gov
    • 05 May 2009 Actual number of patients (70) added as reported by ClinicalTrials.gov
    • 21 Jul 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top